10-K: Oramed Pharmaceuticals Inc. Reports 2024 Annual Results, Highlights Strategic Developments

Oramed Pharmaceuticals Inc. files its 10-K, detailing financial results for 2024 and outlining strategic initiatives including a joint venture for oral insulin development and real estate investments.

Summary

• Oramed Pharmaceuticals Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• A Phase 3 oral insulin trial (ORA-D-013-1) did not meet its primary or secondary endpoints, leading to its termination and a parallel trial (ORA-D-013-2).
• Analysis of the ORA-D-013-1 data identified subpopulations that responded well to oral insulin, leading to the submission of a revised Phase 3 clinical trial protocol (ORA-D-013-3) to the FDA, with study initiation planned for 2025.
• Oramed entered into a joint venture agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT) to form OraTech Pharmaceuticals, Inc. to develop and commercialize oral insulin, with HTIT investing $40 million and Oramed investing $7.5 million at the initial closing, and additional investments contingent on OraTech's Nasdaq listing.
• Oramed engaged in a 2023 Scilex Transaction involving a senior secured promissory note and warrants, and a 2024 Refinancing involving Tranche B Notes and warrants.
• The company participated in a registered direct offering by BioXcel Therapeutics, Inc., acquiring shares and warrants.
• Oramed invested in real estate, including land acquisition in Mevaseret Zion, Israel, and financing for a real estate asset purchase in Jerusalem, Israel.
• The company is evaluating strategic opportunities to enhance stockholder value.
• As of December 31, 2024, Oramed had cash and short-term deposits totaling approximately $109.7 million.
• The company had a net loss of $19.1 million for the year ended December 31, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as the formation of a joint venture and real estate investments, the company also faces challenges including a failed clinical trial and a net loss. The strategic review process adds uncertainty.

Positives

• Formation of OraTech Pharmaceuticals, Inc. joint venture with HTIT to advance oral insulin development and commercialization.
• Extension of Tranche A Note maturity date provides Scilex additional time to repay the debt.
• Real estate investments offer potential long-term value appreciation and income streams.
• The company has a strong working capital position of approximately $137.5 million as of December 31, 2024.
• Participation in BioXcel Therapeutics, Inc. diversifies investments.

Negatives

• Phase 3 oral insulin trial (ORA-D-013-1) did not meet its primary or secondary endpoints.
• The company incurred a net loss of $19.1 million for the year ended December 31, 2024.
• Scilex has disclosed in its periodic reports filed with the SEC that there is substantial doubt about its ability to continue as a going concern.
• The company is exposed to fluctuations in currency exchange rates.

Risks

• The strategic review process may not be successful or timely.
• The company may be unable to protect its intellectual property rights and may be liable for infringing the intellectual property rights of others.
• The company may have difficulty realizing the full value of the Warrants.
• The company is affected by the political, economic and military risks of having operations in Israel.
• The company's investments in real estate may expose it to market and liquidity risks.

Future Outlook

Oramed intends to initiate a revised Phase 3 clinical trial for oral insulin in 2025 and is evaluating strategic opportunities to enhance stockholder value.

Industry Context

The announcement highlights the challenges and risks inherent in pharmaceutical research and development, particularly in the competitive diabetes treatment market. The strategic shift towards a joint venture and real estate investments reflects a broader trend of biotech companies diversifying their assets and revenue streams.

Comparison to Industry Standards

• Given the lack of profitability and reliance on strategic partnerships, Oramed's financial performance is below industry standards for established pharmaceutical companies like Eli Lilly and Novo Nordisk, which have consistent revenue streams from marketed products.
• However, the company's strategic shift towards a joint venture and real estate investments reflects a broader trend of biotech companies diversifying their assets and revenue streams, similar to companies like Royalty Pharma that focus on acquiring royalty interests in established drugs.
• The company's R&D spending is lower than industry averages for companies in late-stage clinical trials, reflecting the impact of the terminated trials and strategic review process.

Corporate Governance

Related Party Transactions

• The company has consulting agreements with KNRY Ltd. and Shnida Ltd., owned by the Chief Scientific Officer and President/CEO, respectively.
• The company has an employment agreement with the President/CEO for services provided to the subsidiary, Oramed Ltd.

Stakeholder Impact

• Shareholders face uncertainty due to the failed clinical trial and strategic review process.
• Employees may experience changes related to the strategic review and joint venture.
• The company's ability to develop and commercialize oral insulin could impact patients with diabetes.

Next Steps

• Initiate a revised Phase 3 clinical trial (ORA-D-013-3) for oral insulin in 2025.
• Complete the initial and second closings of the joint venture agreement with HTIT.
• Continue evaluating strategic opportunities to enhance stockholder value.

Key Dates

Keywords

oral insulin, Oramed, Scilex, OraTech, HTIT, diabetes, clinical trial, pharmaceutical, investment, real estate